Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
about
Rational Use of Recombinant Factor VIIa in Clinical PracticeRecombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials.Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers.Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)Clinical utilization of the international normalized ratio (INR).Illustrated operative management of spontaneous bleeding and compartment syndrome of the lower extremity in a patient with acquired hemophilia A: a case report.Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsContinuous infusion of coagulation factor products.Single center experience on dosing and adverse events of recombinant factor seven use for bleeding after congenital heart surgery.Factor VII Deficiency.Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.The pharmacokinetics of clotting factor therapy.Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleedingRecombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation.Treatment of factor XI inhibitor using recombinant activated factor VIIa.Recombinant factor VIIa in the treatment of non-hemophiliac bleeding.The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.Design and characterization of an APC-specific serpin for the treatment of hemophilia.Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patientsThe role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference.Overview of the human pharmacokinetics of recombinant activated factor VII.Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events.Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients.Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin.Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids.Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.Advances in the treatment of inherited coagulation disorders.
P2860
Q26829915-947D2CB3-228D-455B-B6D6-0A0CA22B0028Q30312208-463B0606-195E-47D0-B0AF-8DE2A4C5BEB0Q30437658-522BA74E-A6C4-42F8-9906-92FEEC360624Q33381758-85B7BAB2-FF97-45E4-A0DE-DA0506997F4EQ33382014-C43E9C52-B347-4916-AA36-543B7459B7DEQ33768400-339F0091-5C2C-42A0-AB18-EEE5985C41DAQ33910636-2BD8AA6E-3959-4E9D-9B7C-74B67B1E56CAQ33942704-A3143190-5C44-47C7-80D1-47F5EBC31292Q34274196-3D5239CC-BF63-41C7-98C5-1D282E6B88EBQ34503723-6AB0EEB5-4294-407B-B82C-F3E025072518Q34538372-B1693768-7F95-469D-A8FE-5A32DF3E25A0Q34615620-024902AC-E8A9-4CC8-B3DA-9E035367D2AFQ34759669-CFAB582E-DDB2-4890-B099-A0A52F3C741EQ34786241-99E1CC15-39E3-410A-9FCC-6AF9019333F8Q35096654-B592F57A-ECF4-4025-845E-9A17D9F59019Q35163599-220C4B43-0598-467E-B2C2-07DF7A05B133Q35544621-A0196084-1F6A-4356-9D19-9B0C89C20439Q35771690-AE2229FC-CE26-4EC0-A838-F3ADFC15D4D9Q35879063-CB11A29D-BCF6-4538-809C-8C4B52A221CDQ35882779-FF2776CC-C2EF-4FFE-876E-868BD74F15A2Q36014991-A22D2792-A743-42B0-9341-65EAF4A23722Q36077574-EBCE130F-2DDE-49A7-A6E2-8607B30750F8Q36150578-0E7C5BBA-D1FE-4FC9-8588-F77988406D1CQ36176667-ABF51D1B-A3F6-4286-9D25-1FFDB5779D06Q36536184-C28B47B6-29B2-4CFC-83FD-94C1E89F8EF2Q36745575-6BD996C2-07AB-4BFC-8757-9C7B455EB916Q36865488-31E1970D-E88F-4B49-879E-3E844F56A9E8Q36981748-37713E35-28AE-4D25-B826-B71E2B83529FQ37419515-6F27E757-09FD-4AE2-BFFE-6ECF3865876EQ37428055-C5F0CA53-CBC4-42C0-80AF-CB31CC7EF0D2Q37539000-1153FCED-39C5-456C-9F0B-4AA7CF4102BCQ37570030-DB174614-13EC-4E82-A9BD-C3B3256F3476Q37586365-D3F23046-58EF-4E2E-AF3F-C90541D2421AQ37679949-46046D97-8C6B-4A5F-968C-D9638099F5FFQ37778292-370573EC-D9B8-4845-BE81-1413A8F0E396Q37790614-F3DB0EC6-7D3A-4CE6-BA6C-1A37C9D26991Q37832976-69FAC342-D221-4544-9F93-29B4A237AD5AQ38007933-CC40A568-EC9C-4D15-A754-10F01220519EQ38011809-363B6439-A1BD-483D-9479-A78F18C17EA8Q38100271-AC71ED3E-FBF2-4245-9257-A3E37305B3A6
P2860
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
@en
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
@nl
type
label
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
@en
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
@nl
prefLabel
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
@en
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
@nl
P2093
P356
P1476
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
@en
P2093
Baird-Cox K
Harrison JF
Lindley CM
Roberts HR
P304
P356
10.1038/CLPT.1994.80
P407
P577
1994-06-01T00:00:00Z